
Claims


1. A compound of formula (I)




(I)

or a pharmaceutically acceptable prodrug, salt and/or solvate thereof, wherein

LHS is selected from the group consisting of LHSa and LHSb



LHSa



LHSb

wherein, the asterisk (*) marks the point of attachment;

Y is selected from the group consisting of CH_2, NH, and NR_d;

Q_1 is selected from the group consisting of O, S, NH and N-C_{1-4}-alkyl;

R_0 is selected from the group consisting of CH_3 and Cl, or alternatively R_0 together with R_{14} form a heterocycle comprising the N to which R_{14} is attached and having 5 to 8 ring members, wherein preferably the only heteroatom in said ring is the N to which R_{14} is attached;

R_1 is selected from the group consisting of H, F, Cl, Br, I, C_{1-4}-alkyl, OR_5, CN, NR_5R_6, CO-NR_5R_6, C_{1-4}-alkylene-NR_5R_6, C_{1-4}-alkylene-OR_5, NH-CO-C_{1-4}-alkylene-R_5, NH-CO-NR_5R_6, NH-$COOR_5$, $NHSO_2$-C_{1-4}-alkylene-R_5, C_{3-6}-cycloalkyl, phenyl, and a heterocyclic group having 5 or 6 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein said C_{1-4}-alkyl , cycloalkyl, phenyl, or heterocyclic group may optionally be substituted with 1-3 R_7 groups;

R_2 is selected from the group consisting of H, F, Cl, Br, I, C_{1-4}-alkyl, OR_5, C_{1-4}-alkylene-OR_5, CN, NR_5R_6, CO-NR_5R_6, C_{1-4}-alkylene-NR_5R_6, C_{3-6}-cycloalkyl, phenyl, and a heterocyclic group having 5 or 6 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein said C_{1-4}-alkyl, cycloalkyl, phenyl, or heterocyclic group may optionally be substituted with 1-3 R_7 groups;

R_3 is selected from the group consisting of H, F, Cl, Br, I, CN, C_{1-4}-alkyl, O-C_{1-4} alkyl, OH, NH_2, NHC_{1-4}-alkyl, and S-C_{1-4}-alkyl;

R_{3a}, R_{3b} and R_{3c} are independently selected from the group consisting of H, F, Cl, Br, I, CN, C_{1-4}-alkyl, O-C_{1-4}-alkyl, OH, NH_2, NHC_{1-4}-alkyl, and S-C_{1-4}-alkyl;

R_4 is selected from the group consisting of H, F, Cl, Br, I, C_{1-4}-alkyl, OR_5, CN, COR_{10}, phenyl, OH, NH_2, S-C_{1-4}-alkyl, NR_5R_6, and a heterocyclic group having 5 or 6 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S;

R_5 and R_6 are independently selected from is selected from the group consisting of H, COR_{10}, C_{1-4}-alkyl, C_{3-6}-cycloalkyl, SO_2R_7, phenyl, and a heterocyclic group having 5 or 6 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein said cycloalkyl, phenyl, or heterocyclic group may optionally be substituted with 1-3 R_7 groups;

R_7 is selected from the group consisting of H, F, I, Br, Cl, O, C_{1-4}-alkyl, $CONH_2$, OH, NH_2, O-C_{1-4}-alkyl, NH-C_{1-4}-alkyl, $N(C_{1-4}\text{-alkyl})_2$, C_{1-4}-alkylene-OH, and C_{1-4}-alkylene-NH_2, NO_2, CN, C_{2-4}-alkenyl, C_{2-4}-alkynyl, C_{2-4}-alkynylene-OH, C_{2-4}-alkynylene-NH_2, SO_2CH_3, and O-C_{1-4}-alkylene-OH;

R_8 and R_9 are independently selected from the group consisting of H, C_{1-4}-alkyl, C_{1-4}-alkyl-F, CN, OH, NH_2, O-C_{1-4}-alkyl, NH-C_{1-4}-alkyl, $N(C_{1-4}\text{-alkyl})_2$, C_{1-4}-alkylene-OH, and C_{1-4}-alkylene-NH_2;

R_{10} is selected from the group consisting of H, C_{1-4}-alkyl, C_{1-4}-alkyl-F, C_{1-4}-alkylene-OH, and C_{1-4}-alkylene-NH_2;

R_{11} and R_{12} are independently selected from the group consisting of H, R_d, C_{1-4}-alkyl, CO-C_{1-4}-alkyl, $SO_2(C_{1-4}\text{-alkyl})_1$, C_{1-4}-alkyl-F, C_{1-4}-alkylene-OH, and C_{1-4}-alkylene-NH_2, or alternatively, R_{11} and R_{12} together with the N to which they are attached form a heterocyclic group having 4 to 9 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S or form a heterocyclic spiro group having 7 to 11 ring members and 1, 2 or 3 heteroatoms independently

selected from N, O and S, wherein said heterocyclic or heterocyclic spiro group may be substituted with 1-3 R_7 groups;

R_{13} is selected from the group consisting of H or R_d;

R_{14} is CH_3, or alternatively R_{14} together with R_0 of LHS_a or LHS_b form a heterocycle comprising the N to which R_{14} is attached and having 5 to 8 ring members, wherein preferably the only heteroatom in said ring is the N to which R_{14} is attached;

and,

R_d is selected from the group consisting of $-PO_3R_{e2}$, $-CH_2-OPO_3R_{e2}$, wherein R_e is selected from the group consisting of H and a cation suitable for forming a pharmaceutically acceptable salt.

2. A compound according to claim 1 wherein LHS is LHSa.

3. A compound according to claim 1 wherein LHS is LHSb.

4. A compound according to any one of claims 1 to 3 wherein Q_1 is selected from the group consisting of O or S.

5. A compound according to any one of claims 1 to 4 wherein R_0 is CH_3 and R_{14} is CH_3.

6. A compound according to any one of claims 1 to 4 wherein R_0 together with R_{14} form a heterocycle comprising the N to which R_{14} is attached and having 5 to 8, preferably 7 ring members, wherein preferably the only heteroatom in said ring is the N to which R_{14} is attached.

7. A compound according to any one of claims 1 to 6 wherein R_1 is selected from the group consisting of H, F, Cl, Br, C_{1-4}-alkyl, OR_5, CN, NR_5R_6, C_{1-4}-alkylene-NR_5R_6, C_{1-4}-alkylene-OR_5, NH-CO-C_{1-4}-alkylene-R_5, NH-CO-NR_5R_6, NH-$COOR_5$, $NHSO_2$-C_{1-4}-alkylene-R_5, C_{3-6}-cycloalkyl, phenyl, and a heterocyclic group having 5 or 6 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein said C_{1-4}-alkyl, cycloalkyl, phenyl, or heterocyclic group may optionally be substituted with 1-3 R_7 groups, and preferably wherein R_1 is selected from the group consisting of H, F, Cl, C_{1-4}-alkyl, OR_5, NR_5R_6, C_{1-4}-alkylene-NR_5R_6, C_{1-4}-alkylene-OR_5, C_{3-6}-cycloalkyl, phenyl, and a heterocyclic group having 5 or 6 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein said C_{1-4}-alkyl, cycloalkyl, phenyl, or heterocyclic group may optionally be substituted with 1-3 R_7 groups, wherein R_5, R_6 and R_7 are as specified in claim 1.

8. A compound according to any one of claims 1 to 7 wherein R_2 is selected from the group consisting of H, F, Cl, Br, C_{1-4}-alkyl, OR_5, C_{1-4}-alkylene-OR_5, CN, NR_5R_6, C_{1-4}-alkylene-NR_5R_6, C_{3-6}-cycloalkyl, wherein said C_{1-4}-alkyl and cycloalkyl may optionally be substituted with 1-3 R_7 groups, and preferably wherein R_2 is selected from the group consisting of C_{1-4}-alkyl, H, F, Cl, OR_5, and NR_5R_6, wherein R_5, R_6 and R_7 are as specified in claim 1.

9. A compound according to anyone of claims 1 to 8 wherein R_3 is selected from the group consisting of H, F, Cl, Br, OH, NH_2, and NHC_{1-4}-alkyl, and preferably wherein R_3 is selected from the group consisting of H, F, Cl, OH, and NH_2.

10. A compound according to any one of claims 1 to 9 wherein R_{3a}, R_{3b} and R_{3c} are independently selected from the group consisting of H, F, Cl, Br, OH, NH_2, and NHC_{1-4}-alkyl, and preferably wherein R_{3a}, R_{3b} and R_{3c} are independently selected from the group consisting of H, F, Cl, OH, and NH_2.

11. A compound according to any one of claims 1 to 10 wherein R_4 is selected from the group consisting of H, F, Cl, Br, OR_5, COR_{10}, OH, NH_2, and NR_5R_6, and wherein R_4 is preferably selected from the group consisting of H, F, Cl, OR_5, OH, NH_2, and NR_5R_6, wherein R_5, R_6 and R_{10} are as specified in claim 1.

12. A compound according to any one of claims 1 to 11 wherein R_7 is selected from the group consisting of H, F, C_{1-4}-alkyl, C_{2-4}-alkenyl, C_{2-4}-alkynyl, OH, NH_2, O-C_{1-4}-alkyl, NH-C_{1-4}-alkyl, N(C_{1-4}-alkyl)$_2$, C_{1-4}-alkylene-OH, C_{1-4}-alkylene-NH_2, and O-C_{1-4}-alkylene-OH, C_{2-4}-alkynylene-OH, and C_{2-4}-alkynylene-NH_2 and preferably wherein R_7 is selected from the group consisting of H, F, C_{1-4}-alkyl, OH, NH2, O-C_{1-4}-alkyl, NH-C_{1-4}-alkyl, N(C_{1-4}-alkyl)$_2$, C_{1-4}-alkylene-OH, and C_{1-4}-alkylene-NH_2.

13. A compound according to anyone of claims 1 to 12 wherein R_8 and R_9 are independently selected from the group consisting of H, C_{1-4}-alkyl, C_{1-4}-alkyl-F, O-C_{1-4}-alkyl, and preferably wherein R_8 and R_9 are independently selected from the group consisting of H, and C_{1-4}-alkyl.

14. A compound according to anyone of claims 1 to 13 wherein R_{10} is selected from the group consisting of H, C_{1-4}-alkyl, C_{1-4}-alkyl-F, and preferably wherein R_{10} is selected from the group consisting of H, and C_{1-4}-alkyl.

15. A compound according to anyone of claims 1 to 14 wherein R_{11} and R_{12} are independently selected from the group consisting of H, R_d, C_{1-4}-alkyl, C_{1-4}-alkyl-F, C_{1-4}-alkylene-OH, and C_{1-4}-alkylene-NH_2, or alternatively, R_{11} and R_{12} together with the N to which they are attached form a heterocyclic group having 4 to 9 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S or form a heterocyclic spiro group having 7 to 11 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein said heterocyclic or heterocyclic spiro group may be substituted with 1-3 R_7 groups and wherein preferably R_{11} and R_{12} are independently selected from the group consisting of H, R_d, and C_{1-4}-alkyl, wherein R_7 and R_d are as specified in claim 1.

16. A compound according to anyone of claims 1 to 15 wherein,

R_1 is selected from the group consisting of H, F, Cl, Br, C_{1-4}-alkyl, OR_5, NR_5R_6, C_{1-4}-alkylene-NR_5R_6, C_{1-4}-alkylene-OR_5, NH-CO-C_{1-4}-alkylene-R_5, NH-CO-NR_5R_6, NH-$COOR_5$, $NHSO_2$-C_{1-4}-alkylene-R_5, C_{3-6}-cycloalkyl, wherein said C_{1-4}-alkyl and cycloalkyl may optionally be substituted with 1-3 R_7 groups, and preferably is selected from the group consisting of H, F, Cl, C_{1-4}-alkyl, OR_5, NR_5R_6, C_{1-4}-alkylene-NR_5R_6, C_{1-4}-alkylene-OR_5, C_{3-6}-cycloalkyl, phenyl, and a heterocyclic group having 5 or 6 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein said C_{1-4}-alkyl, cycloalkyl, phenyl, or heterocyclic group may optionally be substituted with 1-3 R_7 groups;

R_2 is selected from the group consisting of H, F, Cl, Br, C_{1-4}-alkyl, OR_5, C_{1-4}-alkylene-OR_5, CN, NR_5R_6, C_{1-4}-alkylene-NR_5R_6, C_{3-6}-cycloalkyl, wherein said C_{1-4}-alkyl, cycloalkyl, phenyl, or heterocyclic group may optionally be substituted with 1-3 R_7 groups, and preferably is selected from the group consisting of H, F, Cl, OR_5, C_{1-4}-alkyl, and NR_5R_6;

R_3 is selected from the group consisting of H, F, Cl, Br, OH, NH_2, and NHC_{1-4}-alkyl, and preferably is selected from the group consisting of H, F, Cl, OH, and NH_2;

R_{3a}, R_{3b} and R_{3c} are independently selected from the group consisting of H, F, Cl, Br, OH, NH_2, and NHC_{1-4}-alkyl, and preferably are independently selected from the group consisting of H, F, Cl, OH, and NH_2;

R_4 is selected from the group consisting of H, F, Cl, Br, OR_5, COR_{10}, OH, NH_2, and NR_5R_6, and preferably is selected from the group consisting of H, F, Cl, OR_5, OH, NH_2, and NR_5R_6;

R_7 is selected from the group consisting of H, F, C_{1-4}-alkyl, C_{2-4}-alkenyl, C_{2-4}-alkynyl, OH, NH_2, O-C_{1-4}-alkyl, NH-C_{1-4}-alkyl, N(C_{1-4}-alkyl)$_2$, C_{1-4}-alkylene-OH, and C_{1-4}-alkylene-NH_2, O-C_{1-4}-alkylene-OH, C_{2-4}-alkynylene-OH, and C_{2-4}-alkynylene-NH_2, and preferably is selected from the group consisting of H, F, C_{1-4}-alkyl, OH, NH_2, O-C_{1-4}-alkyl, NH-C_{1-4}-alkyl, N(C_{1-4}-alkyl)$_2$, C_{1-4}-alkylene-OH, and C_{1-4}-alkylene-NH_2;

R_8 and R_9 are independently selected from the group consisting of H, C_{1-4}-alkyl, C_{1-4}-alkyl-F, and O-C_{1-4}-alkyl, and preferably are independently selected from the group consisting of H, and C_{1-4}-alkyl;

R_{10} is selected from the group consisting of H, C_{1-4}-alkyl, and C_{1-4}-alkyl-F, and preferably from the group consisting of H, and C_{1-4}-alkyl;

and,

R_{11} and R_{12} are independently selected from the group consisting of H, R_d, C_{1-4}-alkyl, C_{1-4}-alkyl-F, C_{1-4}-alkylene-OH, and C_{1-4}-alkylene-NH_2, or alternatively, R_{11} and R_{12} together with the N to which they are attached form a heterocyclic group having 4 to 9 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S or form a heterocyclic spiro group having 7 to 11 ring members and 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein said heterocyclic or heterocyclic spiro group may be substituted with 1-3 R_7 groups, and wherein preferably R_{11} and R_{12} are independently selected from the group consisting of H, R_d, and C_{1-4}-alkyl, wherein R_5, R_6 and R_d are as specified in claim 1.

17. A compound according to any one of claims 1 to 16 wherein Y is CH_2.

18. A compound according to any one of claims 1 or 17 wherein Y is NH.

19. A compound according to claim 1 selected from the group consisting of (E)-3-((2R,3S)-3-Amino-2-methyl-4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)-N-((7-amino-2-methylbenzofuran-3-yl)methyl)-N-methylacrylamide, (E)-3-((2R,3S)-3-amino-2-methyl-4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide, E)-3-(3-acetamido-4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide, (S,E)-N-methyl-N-((2-methylbenzofuran-3-yl)methyl)-3-(4-oxo-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-2,3,4,5-tetrahydro-


1H-pyrido[2,3-b][1,4]diazepin-8-yl)acrylamide, E)-3-((R)-3-((2S,6R)-2,6-dimethylmorpholino)-4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide, and (S,E)-3-(3-amino-4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)-N-methyl-N-((3-methylbenzofuran-2-l)methyl)acrylamide, (E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-((7-chloro-3-methylbenzofuran-2-yl)methyl)-N-methylacrylamide, (E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((2-methylbenzofuran-3-yl)methyl)acrylamide, (S,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide, (E)-3-(7-(dimethylamino)-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide, (S,E)-3-(7-(dimethylamino)-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide, (S,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-((7-chloro-3-methylbenzofuran-2-yl)methyl)-N-methylacrylamide, (S,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-((7-fluoro-3-methylbenzofuran-2-yl)methyl)-N-methylacrylamide, (S,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methylbenzo[b]thiophen-2-yl)methyl)acrylamide, (S,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-((4-fluoro-3-methylbenzofuran-2-yl)methyl)-N-methylacrylamide, (S,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-((7-fluoro-3-methylbenzo[b]thiophen-2-yl)methyl)-N-methylacrylamide, (S,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methyl-5-(pyridin-3-yloxy)benzofuran-2-yl)methyl)acrylamide, (E)-3-((S)-7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-((4-(((1r,4r)-4-aminocyclohexyl)oxy)-3-methylbenzofuran-2-yl)methyl)-N-methylacrylamide, (S,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methyl-4-((pyridin-3-ylamino)methyl)benzofuran-2-yl)methyl)acrylamide, (S,E)-N-((7-fluoro-3-methylbenzofuran-2-yl)methyl)-N-methyl-3-(7-morpholino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)acrylamide, (E)-N-methyl-N-((2-methylbenzofuran-3-yl)methyl)-3-(7-morpholino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)acrylamide, (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(8-oxo-7-(7-oxa-2-azaspiro[3.5]nonan-2-yl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)acrylamide, (E)-3-(7-(1,1-Dioxidothiomorpholino)-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide, (E)-N-Methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(8-oxo-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)acrylamide, (E)-N-Methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-(4-(methylsulfonyl)piperazin-1-yl)-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)acrylamide,

S,E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(8-oxo-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)acrylamide, ((S,E)-3-(7-(3-hydroxyazetidin-1-yl)-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide, (E)-N-((7-Amino-2-methylbenzofuran-3-yl)methyl)-N-methyl-3-(8-oxo-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)acrylamide, (S,E)-N-((7-amino-2-methylbenzofuran-3-yl)methyl)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methylacrylamide, and (E)-3-((2R,3S)-3-hydroxy-2-methyl-4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)-N-methyl-N-((3-methyl-4-(pyridin-3-yloxy)benzofuran-2-yl)methyl)acrylamide, (S,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((2-methylbenzofuran-3-yl)methyl)acrylamide and any pharmaceutically acceptable prodrugs, salts and/or solvates thereof.


20. A pharmaceutical composition comprising a compound according to any preceding claim.

21. Use of ~~A~~a compound or composition according to any preceding claims in the manufacture of a medicament for ~~for use in a method of therapy wherein preferably the method of therapy is a method of~~ treating a bacterial infection and wherein preferably the bacterial infection is associated with one or more of bacteria selected from the group consisting of: *S. aureus, E. coli, Klebsiella pneumoniae and A. baumannii and most preferably wherein* the bacterial infection is associated with *A. baumannii* and is preferably pneumonia and most preferably nosocomial pneumonia.

22. A method for producing a compound as defined in anyone of claims 1 to 19 wherein said method is selected from a first variant that comprises the step of coupling a precursor compound of formula M1 or M1'




M1




M1'

wherein X represents a leaving group, which is preferably selected from a hydroxyl group, a tosylate group, a triflate group, a mesylate group, iodide, bromide, chloride, methoxy, and ethoxy, and Pg represents a protective group, which is preferably selected from the Boc group, PMB group, and DMB group, and R_{11} and or R_{12} in addition of being defined as herein may also comprise a protective group, which is preferably selected from the Boc group, PMB group, and DMB group,

with an amine compound of formula M2a or M2b, as appropriate







M2a, M2b

wherein Y, Q_1, and all R groups have the same meanings as specified in items 1 to 18;


and a second variant that comprises the step of coupling a compound of formula M6 or M6'






M6 M6'

with a compound of formula M7a or M7b, as appropriate





M7a M7b

wherein Pg represents a protective group, which is preferably selected from the Boc group, PMB group, and DMB group, wherein Y, Q_1 and all R groups have the same meaning as specified in claims 1 to 19, wherein R_{11} and R_{12} may be a group as defined in any of claims 1 to 19 or may be such a defined group that also comprises a protective group, which is preferably selected from the Boc group, PMB group, and DMB group.